News Feed Opinion Blog Career Insight Dialogues Celebrities Oncolibrary
Positive Societies Drugs Stories History Cancer Center Near Me Cancer Types Immune Oncology Oncologist Near Me
January, 2025
January 2025
M T W T F S S
 12345
6789101112
13141516171819
20212223242526
2728293031  
Eribulin + HP as first-line treatment of locally advanced/metastatic HER2+ breast cancer
health365.sg
Jan 12, 2025, 08:51

Eribulin + HP as first-line treatment of locally advanced/metastatic HER2+ breast cancer

Elisabetta Bonzano, Radiation Oncologist at IRCCS San Matteo Polyclinic Foundation, shared on X:

“Trastuzumab-Pertuzumab Plus Eribulin or Taxane as First-Line Chemotherapy for Human Epidermal Growth Factor 2–Positive Locally Advanced/Metastatic Breast Cancer: The Randomized Noninferiority Phase III EMERALD Trial

The results suggested that eribulin + HP is an option for first-line treatment of locally advanced/metastatic HER2+ BC.”

Eribulin + HP as first-line treatment of locally advanced/metastatic HER2+ breast cancer

Trastuzumab-Pertuzumab Plus Eribulin or Taxane as First-Line Chemotherapy for Human Epidermal Growth Factor 2–Positive Locally Advanced/Metastatic Breast Cancer: The Randomized Noninferiority Phase III EMERALD Trial | Journal of Clinical Oncology

Authors: Toshinari Yamashita, Shigehira Saji, Toshimi Takano, Yoichi Naito, Michiko Tsuneizumi, Akiyo Yoshimura, Masato Takahashi, Junji Tsurutani, Tsuguo Iwatani, Masahiro Kitada, Hiroshi Tada,  Natsuko Mori, Toru Higuchi, Tsutomu Iwasa, Kazuhiro Araki, Kei Koizumi,  Hiroki Hasegawa, Yohei Uchida, Satoshi Morita, Norikazu Masuda.

Eribulin + HP as first-line treatment of locally advanced/metastatic HER2+ breast cancer

Akiyo Yoshimura cancer Elisabetta Bonzano Hiroki Hasegawa Hiroshi Tada Junji Tsurutani Kazuhiro Araki Kei Koizumi Masahiro Kitada Masato Takahashi Michiko Tsuneizumi Natsuko Mori Norikazu Masuda OncoDaily Oncology Satoshi Morita Shigehira Saji Toru Higuchi Toshimi Takano Toshinari Yamashita Tsuguo Iwatani Tsutomu Iwasa Yohei Uchida Yoichi Naito
Special Coverage
Blog
Jan 12, 2025, 08:51
Eribulin + HP as first-line treatment of locally advanced/metastatic HER2+ breast cancer
Blog
Jan 12, 2025, 08:44
Isabel Preeshagul: Addressing barriers to clinical trial accrual in patients with lung cancer
Blog
Jan 12, 2025, 08:00
Implementation of AI for cancer detection in population-based mammography screening
Blog
Jan 12, 2025, 07:53
Ponsegromab as a novel, targeted therapy to address unmet needs of patients with cancer and cachexia
Blog
Jan 12, 2025, 07:18
Northern Ireland is now among the first places in the world to estimate how many people are living secondary breast cancer
Insight
Jan 12, 2025, 07:12
Pfizer’s Sasanlimab with BCG Improved Event-Free Survival in High-Risk Bladder Cancer
Insight
Jan 12, 2025, 07:07
Elvina Almuradova: ctDNA/MRD testing shows promise in guiding colon cancer treatment
Blog
Jan 12, 2025, 07:02
A new guideline update on the treatment of pleural mesothelioma - ASCO
Insight
Jan 12, 2025, 06:53
Drew Moghanaki: More fuel to the fire on debates about "more immunotherapy" after surgery
Insight
Jan 12, 2025, 06:45
Richard Buka: TPO-RA - Sustained Responses in ITP After Stopping Treatment
Blog
Jan 12, 2025, 06:39
Applications are open for Health Volunteers Overseas’s hematology program in Dar es Salaam - ASH
Insight
Jan 12, 2025, 06:34
Ilana Schlam: Great review led by Tess O’Meara on ADCs in breast cancer